For research use only — not for human consumption
Journal compound
Journal articles on BPC-157 research: mechanism, published studies, and analytical data. For laboratory research use only.
BPC-157 and TB-500 are often discussed as a pair. Their sequences, mechanisms and research histories are different, and the evidence behind each is thinner than the discussion suggests.
Read article →Repaired tissue tops out at about 80% of its original strength, and the usual bottleneck is the arrival of new blood vessels during the proliferation phase.
Read article →In a 2026 rat Achilles tendon study, TB-500 increased maximum load to failure versus controls. Combining it with BPC-157 added no benefit over either alone.
Read article →Five claims the peptide internet repeats, from GHK-Cu gene counts to fridge storage, and what the research actually says about each.
Read article →Tendons receive far less blood than muscle, which is why they repair slowly. Here is what the BPC-157 tendon studies measured, and what they leave open.
Read article →The FDA is reviewing whether BPC-157, TB-500 and other peptides leave the compounding-restricted category. It would open one channel and leave the rest unchanged.
Read article →Most peptides degrade quickly in stomach acid. BPC-157, a fragment of a protective gastric protein, does not, and that stability is where its research story starts.
Read article →Mandatory research disclaimer
All materials on this site are sold as laboratory reagents for research use only. They are not drugs, foods, cosmetics, dietary supplements, or medical devices, and are not for human or veterinary use of any kind.
Senna Research makes no claims of safety or efficacy and provides no usage, dosing, or preparation guidance; we publish analytical data only.
These materials have not been evaluated or approved by the U.S. Food and Drug Administration for any use.
